0000950170-23-002893.txt : 20230215 0000950170-23-002893.hdr.sgml : 20230215 20230215160631 ACCESSION NUMBER: 0000950170-23-002893 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230215 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230215 DATE AS OF CHANGE: 20230215 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASSEMBLY BIOSCIENCES, INC. CENTRAL INDEX KEY: 0001426800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35005 FILM NUMBER: 23635390 BUSINESS ADDRESS: STREET 1: 331 OYSTER POINT BLVD. STREET 2: FOURTH FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (833) 409-4583 MAIL ADDRESS: STREET 1: 331 OYSTER POINT BLVD. STREET 2: FOURTH FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: VENTRUS BIOSCIENCES INC DATE OF NAME CHANGE: 20080211 8-K 1 asmb-20230215.htm 8-K 8-K
0001426800false00014268002023-02-152023-02-15

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 15, 2023

 

Assembly Biosciences, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-35005

20-8729264

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

331 Oyster Point Blvd., Fourth Floor,

South San Francisco, California

 

94080

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (833) 509-4583

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.001

 

ASMB

 

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 8.01 Other Events.

On February 15, 2023, Assembly Biosciences, Inc. issued a press release announcing the nomination of its first herpesvirus development candidate, ABI-5366, a long-acting herpes simplex virus type 2 helicase inhibitor targeting high-recurrence genital herpes.

A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit

Number

 

Description

99.1

 

Press Release dated February 15, 2023.

 104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

1

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

Assembly Biosciences, Inc.

 

 

 

 

Date: February 15, 2023

 

By:

/s/ John O. Gunderson

 

 

 

John O. Gunderson

 

 

 

VP, General Counsel and Corporate Secretary

 

2

 EX-99 2 asmb-ex99_1.htm EX-99.1 EX-99

Exhibit 99.1

Assembly Biosciences Nominates First Herpesvirus Development Candidate ABI-5366, a Long-Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes

 

−ABI-5366 Demonstrates Favorable Profile for a Long-Acting Therapeutic in Preclinical Studies

−IND-Enabling Studies Initiating for 5366, Supporting Anticipated IND/CTA Filing in 1H2024

SOUTH SAN FRANCISCO, Calif., February 15, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced the selection of development candidate ABI-5366 (5366) to progress to IND-enabling studies for its long-acting herpes simplex virus type 2 (HSV-2) helicase inhibitor program. 5366 is the first development candidate from Assembly Bio’s discovery pipeline nominated for advancement to clinical development since the company announced its expanded research focus outside of hepatitis B last year.

 

“We’re excited to bring forward this novel development candidate from our HSV-2 program targeting high-recurrence genital herpes, a serious chronic viral disease with profound physical and psychological impacts on patients. There has not been a new medicine approved for patients suffering from high-recurrence genital herpes in decades and current therapies are only partially effective in preventing frequent outbreaks,” said William Delaney, PhD, chief scientific officer of Assembly Bio.

 

Assembly Bio’s HSV-2 program targets the viral helicase-primase, an essential viral enzyme complex and a clinically validated target. Helicase inhibition has demonstrated greater reductions in HSV-2 shedding, lesions and pain compared to approved suppressive nucleoside analog regimens in previous clinical studies. 5366, a small molecule helicase inhibitor with nanomolar potency in vitro, is designed for long-acting administration and has shown favorable pharmacokinetics (PK) for a long-acting therapeutic, including the key property of exceptionally low clearance, in preclinical studies. 5366’s preclinical profile shows the potential for at least monthly dosing, and Assembly Bio will continue to evaluate longer dosing intervals as development and formulation progress.

 

“Assembly Bio’s differentiated long-acting approach for HSV-2 offers the potential to maintain optimal drug plasma concentrations over long periods of time. We anticipate this drug profile, supported by 5366’s remarkably low clearance, will enhance both adherence and antiviral activity, leading to better outcomes for patients compared to current suppressive regimens that require daily dosing,” continued Dr. Delaney. “We are excited to continue advancing this promising candidate quickly toward the clinic and sharing more data on 5366 at scientific conferences in 2023.”

 

About High-Recurrence Genital Herpes

 

High-recurrence genital herpes associated with HSV-2 infection is characterized by frequent recurrences of lesions (six or more per year) and is estimated to affect up to 40% of HSV-2

 

 

genital herpes patients following their first outbreak. Approved suppressive therapy regimens consist of oral daily dosing of nucleoside analogs, a class first approved for genital herpes almost three decades ago, with no new drug approvals in the last 20 years. These suppressive regimens have been shown to reduce the recurrence of genital herpes among patients with high HSV-2 recurrence, but eliminate recurrences for only a minority of these patients.

 

About Assembly Biosciences
 

Assembly Biosciences is a clinical-stage biotechnology company dedicated to the development of innovative small molecule antiviral therapeutics with the potential to change the path of serious viral diseases and improve the lives of patients worldwide. The company’s hepatitis B virus (HBV) pipeline includes two potent, next-generation HBV core inhibitors in clinical development, which are designed to disrupt the virus’ replication cycle at several key points with the aim of achieving finite treatment and functional cures. Assembly Bio’s HBV and hepatitis delta virus (HDV) pipeline also includes two complementary approaches, a viral entry inhibitor and an oral, liver-focused, interferon-alpha receptor agonist, with potential application for both HBV and as chronic suppressive therapy for HDV, which is associated with significantly increased disease burden for HBV/HDV patients. The herpesvirus pipeline addresses two serious consequences associated with herpesvirus infections, high-recurrence genital herpes and transplant-associated herpesviruses. Led by an accomplished team of leaders in virologic drug development, Assembly Bio is committed to improving outcomes for patients struggling with the serious, chronic impacts of HBV, HDV and herpesvirus infections. For more information, visit assemblybio.com.

 

Forward-Looking Statements

 

The information in this press release contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to materially differ. These risks and uncertainties include: Assembly Bio’s ability to successfully execute its previously announced reprioritization and restructuring activities, including the CEO transition; potential adverse legal, reputational, operational and financial effects on Assembly Bio resulting from the reprioritization and restructuring activities; Assembly Bio’s ability to initiate and complete clinical studies involving its therapeutic product candidates, including studies contemplated by Assembly Bio’s collaboration agreements, in the currently anticipated timeframes; safety and efficacy data from clinical studies may not warrant further development of Assembly Bio’s product candidates; clinical and nonclinical data presented at conferences may not differentiate Assembly Bio’s product candidates from other companies’ candidates; results of nonclinical studies may not be representative of disease behavior in a clinical setting and may not be predictive of the outcomes of clinical studies; continued development and commercialization of ABI-H3733, if successful, in the China territory will be dependent on, and subject to, Assembly Bio’s collaboration agreement governing this activity in the China territory; Assembly Bio’s ability to maintain financial resources necessary to continue its clinical studies and fund business operations; any impact that the COVID-19 pandemic may have on Assembly Bio’s

 

 

 

 

 

 

business and operations, including initiation, enrollment and continuation of its clinical studies or timing of discussions with regulatory authorities; and other risks identified from time to time in Assembly Bio’s reports filed with the U.S. Securities and Exchange Commission (the SEC). You are urged to consider statements that include the words may, will, would, could, should, might, believes, hopes, estimates, projects, potential, expects, plans, anticipates, intends, continues, forecast, designed, goal or the negative of those words or other comparable words to be uncertain and forward-looking. Assembly Bio intends such forward-looking statements to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. More information about Assembly Bio’s risks and uncertainties are more fully detailed under the heading “Risk Factors” in Assembly Bio’s filings with the SEC, including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Except as required by law, Assembly Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Contacts

Investor and Corporate:
Shannon Ryan
SVP, Investor Relations, Corporate Affairs and Alliance Management
(415) 738-2992
sryan@assemblybio.com

 

Media:
Sam Brown Inc.
Hannah Hurdle
(805) 338-4752
ASMBMedia@sambrown.com 

 

 

 

 

 

 

 

 

 

 EX-101.LAB 3 asmb-20230215_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Address City Or Town Entity Address, City or Town Soliciting Material Soliciting Material Amendment Flag Amendment Flag Entity Incorporation State Country Code Entity Incorporation, State or Country Code City Area Code City Area Code Document Period End Date Document Period End Date Entity Address Postal Zip Code Entity Address, Postal Zip Code Entity File Number Entity File Number Entity Address Address Line1 Entity Address, Address Line One Entity Tax Identification Number Entity Tax Identification Number Entity Emerging Growth Company Entity Emerging Growth Company Entity Registrant Name Entity Registrant Name Pre Commencement Tender Offer Pre-commencement Tender Offer Security12b Title Title of each class Entity Address State Or Province Entity Address, State or Province Document Type Document Type Written Communications Written Communications Security Exchange Name Name of each exchange on which registerd Entity Central Index Key Entity Central Index Key Local Phone Number Local Phone Number Pre Commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Cover [Abstract] Trading Symbol Trading Symbol EX-101.SCH 4 asmb-20230215.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.PRE 5 asmb-20230215_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document And Entity Information
Feb. 15, 2023
Cover [Abstract]  
Entity Registrant Name Assembly Biosciences, Inc.
Document Type 8-K
Amendment Flag false
Entity Central Index Key 0001426800
Document Period End Date Feb. 15, 2023
Entity Emerging Growth Company false
Entity File Number 001-35005
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 20-8729264
Entity Address, Address Line One 331 Oyster Point Blvd., Fourth Floor
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code (833)
Local Phone Number 509-4583
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of each class Common Stock, par value $0.001
Trading Symbol ASMB
Name of each exchange on which registerd NASDAQ
XML 7 asmb-20230215_htm.xml IDEA: XBRL DOCUMENT 0001426800 2023-02-15 2023-02-15 0001426800 false 8-K 2023-02-15 Assembly Biosciences, Inc. DE 001-35005 20-8729264 331 Oyster Point Blvd., Fourth Floor South San Francisco CA 94080 (833) 509-4583 false false false false Common Stock, par value $0.001 ASMB NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.assemblybio.com/20230215/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports asmb-20230215.htm asmb-20230215.xsd asmb-20230215_lab.xml asmb-20230215_pre.xml asmb-ex99_1.htm http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "asmb-20230215.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "asmb-20230215.htm" ] }, "labelLink": { "local": [ "asmb-20230215_lab.xml" ] }, "presentationLink": { "local": [ "asmb-20230215_pre.xml" ] }, "schema": { "local": [ "asmb-20230215.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "asmb", "nsuri": "http://www.assemblybio.com/20230215", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "asmb-20230215.htm", "contextRef": "C_492a0bf2-4bd2-48e2-ae07-9c14d799e0d3", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.assemblybio.com/20230215/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "asmb-20230215.htm", "contextRef": "C_492a0bf2-4bd2-48e2-ae07-9c14d799e0d3", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.assemblybio.com/20230215/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.assemblybio.com/20230215/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.assemblybio.com/20230215/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.assemblybio.com/20230215/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.assemblybio.com/20230215/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.assemblybio.com/20230215/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.assemblybio.com/20230215/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.assemblybio.com/20230215/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.assemblybio.com/20230215/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.assemblybio.com/20230215/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.assemblybio.com/20230215/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.assemblybio.com/20230215/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.assemblybio.com/20230215/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.assemblybio.com/20230215/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.assemblybio.com/20230215/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.assemblybio.com/20230215/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.assemblybio.com/20230215/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of each class" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.assemblybio.com/20230215/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Name of each exchange on which registerd" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.assemblybio.com/20230215/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.assemblybio.com/20230215/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.assemblybio.com/20230215/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.assemblybio.com/20230215/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0000950170-23-002893-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-002893-xbrl.zip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end